Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIFU Hyperthermia with Doxil in Pediatric Solid Tumors
NCT02557854Phase 1Withdrawn
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegylated liposomal doxorubicin in rhabdomyosarcoma (RMS), neuroblastoma, sarcoma and 3 more. Primary endpoint: Rate of dose limiting toxicities at 4 weeks. Planned start Dec 2016; status: withdrawn.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
rhabdomyosarcoma (RMS)neuroblastomasarcomaEwing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT02557854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557854.